Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-286-2 | CAS number: 137-26-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Oral
key (EPA OPP 81 -1) rat: LD50 = 1800 mg/kg bw (females) and 3700 mg/kg bw (males)
Inhalation
key (EPA OPP 81-3), rat: LC50 = >5.04 mg/L (males) and 3.46 mg/L (females)
Dermal
key (EPA OPP 81-2), rabbit: LD50 > 2000 mg/kg bw (males and females)
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 5 Aug - 2 Oct 1985
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Version / remarks:
- not specified
- Deviations:
- not specified
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 81-1 (Acute Oral Toxicity)
- Deviations:
- yes
- Remarks:
- The room temperature was on various occasions, for a total of 18 hours, below the protocolled 19°C. This deviation was not considered to has affected the outcome of the study.
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Central Institute for the Breeding of Laboratory Animals TNO (CPB), Zeist, The Netherlands
- Age at study initiation: 11-14 weeks (male and female)
- Weight at study initiation: 243-359 g (male), 152-186 g (female)
- Fasting period before study: overnight before dosing till approximately 4 hours after administration of the test substance
- Housing: individually housed in Macrolon cages
- Diet: standard laboratory diet (RMH-B, pellet diameter 10 mm, Hope Farms, Woerden, The Netherlands), ad libitum
- Water: tap water, ad libitum
- Acclimation period: 3-7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 18-23
- Humidity (%): 50-85
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: gavage
- Vehicle:
- propylene glycol
- Details on oral exposure:
- VEHICLE
- Amount of vehicle: 10 mL/kg bw - Doses:
- 560, 740, 1300, 2400, 4200 mg/kg bw
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 22 days
- Frequency of observations and weighing: daily for morbitidy, death and clinical signs (except for the day of dosing, were animals were observed 2, 6 and 7.5 h after dosing), animals were weighed on Day 0, 7, 14 and 21
- Necropsy of survivors performed: yes
- Histopathology: At the end of the observation period all surviving animals were scarified and subjected to gross necropsy. Found dead animals were weighed and subjected to gross necropsy. - Key result
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 3 700 mg/kg bw
- 95% CL:
- 2.3 - 19.8
- Remarks on result:
- other: Maximum likelihood according to Finney
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 1 800 mg/kg bw
- Remarks on result:
- other: Maximum likelihood according to Finney
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 2 600 mg/kg bw
- Remarks on result:
- other: Maximum likelihood according to Finney
- Mortality:
- - 560 mg/kg bw: 0/5 males, 1/5 females (Day 1)
- 740 mg/kg bw: 0/5 males, 1/5 females (Day 2)
- 1300 mg/kg bw: 0/5 males, 0/5 females
- 2400 mg/kg bw: 0/5 males, 3/5 females (Day 9, 13 and 22)
- 4200 mg/kg bw: 4/5 males (Day 5, 6, 6 and 7), 5/5 females (Day 3, 7, 8 and 9)
Summarized results can be found in Attachment 1 in the attached background material. - Clinical signs:
- bodyweight loss
- diarrhoea
- lethargy (hypoactivity)
- salivation
- Body weight:
- greater than 10% body weight loss
- Remarks:
- Please refer to "Any other information on results incl. tables".
- Gross pathology:
- Please refer to "Any other information on results incl. tables".
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- The study was conducted according to EPA-OPP 81-1 and under GLP conditions. Under the conditions of this study, the acute oral LD50 of thiram was 3700 mg/kg bw for males and 1800 mg/kg bw for female rats.
In accordance with Regulation (EC) No 1272/2008 the test susbtance should be classified as acute toxic category 4 and the hazard statement H302 “harmful if swallowed" should be assigned.
Reference
Clinical Signs:
- 560 mg/kg bw: Lethargy, (half)-closed eyes, moist eyes reduced respiration in males and females from 1 h to Day 2 post-dosing. In addition, ungroomed appearance (on Day 2) and reduced faecal excretion (on Day 5) was noted in 1/5 females.
- 740 mg/kg bw: Lethargy, (half)-closed eyes, moist eyes, reduced respiration in males and females from 1 h to Day 2 post-dosing. In addition, ungroomed appearance (Day 2, and 8), reduced faecal excretion (Days 4 - 7), and emaciation (Days 6 - 9) was noted in some females.
- 1300 mg/kg bw: Lethargy, (half)-closed eyes, moist eyes, head tremors in males and females from 1 to 6 h post-dosing. In addition, emaciation and pale skin colour was noted in 1/5 females (Day 8).
- 2400 mg/kg bw: Lethargy was noted in all animals of both sexes from 1.5 to 5.5 h after dosing. Males showed lethargy also from day 4 to 7 and Day 12-13. Females shoed lethargy from Day 4 - 13, and Day 18 - 20. Rats of both sexes had closed eyes, moist eyes or salivation within 5.5 h post-dosing. Other signs consisting of bloody eye and nose encrustration, diarrhoea were observed in single animals on some days. In several females bloody eye and nose encrustration, tremors, emaciation, reduced respiration, comatous, ungroomed appearance and reduced faecal excretion were noted throughout the study period.
- 4200 mg/kg bw: Lethargy was noted in all animals of both sexes from 2 to 6 h after dosing, and from Day 4 (females) or Day 6 (males) until death of animals. Other signs, which were observed during the study were emaciation, ungroomed appearance, reduced or absent faecal excretion, pale skin colour, bloody nose or eyes encrustration, laboured breathing in animals of both sexes. Males showed also diarrhoe and tremors, whereas females had closed eyes.
Summarized results can be found in Attachment 1 in the attached background material.
Body weight:
- 560 mg/kg bw: All male and female animals gained weighed during the observation period. In the post-administration period Day 0 – 7, a small weight loss was observed (mean: males -2.7%, females -3.0%), but all animals recovered afterwards. (final mean body weight gain over the observation period: males +18.7%, females +14.3%)
- 740 mg/kg bw: All male and female animals gained weighed during the observation period. In the post-administration period Day 0 – 7, a small weight loss was observed (mean: males -6.5%, females -10.7%), but all animals recovered afterwards (final mean body weight gain over the observation period: males +18.5%, females +16.5%)
- 1300 mg/kg bw: All male and female animals gained weighed during the observation period. In the post-administration period Day 0 – 7, weight loss was observed (mean: males -7.9%, females -5.2%), but all animals recovered afterwards (final mean body weight gain over the observation period: males +12.5%, females +16.6%).
- 2400 mg/kg bw: All male animals gained weighed during the observation period. In the post-administration period Day 0 – 7, weight loss was observed (mean -16.7%), but all animals recovered afterwards (final mean body weight gain over the observation period: +14.7%). Females showed weight loss during the Day 0 – 7 observation period (mean -18.6%), and a partial recovery afterwards (final mean body weight gain over the observation period:-6.3%).
- 4200 mg/kg bw: Weight loss until deaths in all animals.
Summarized results can be found in Attachment 1 in the attached background material.
Pathology:
- 560 mg/kg bw: Autolysis of abdominal organs, yellow to white stomach content, and blood clots were observed in 1/5 females. In males no anomalies were observed.
- 740 mg/kg bw: Autolysis of abdominal organs, foamy white stomach content, blood clots in antral lumen were observed in one female. In males no anomalies
- 1300 mg/kg bw: No abnormalities in males and females were observed.
- 2400 mg/kg bw: Autolysis of abdominal organs, enlarged left adrenal, stomach erosive and containing small blood clots were observed in 1/5 females. In another female small spleen and ovaries, pale kidneys and intestine, no intestinal content, damaged stomach containing white granular substance. Histopathology evaluation of these lesions showed local pyelonephritis of kidney and focal erosion of the stomach. In males no anomalies
- 4200 mg/kg bw: In all males and females stomach findings consisting of white discoloration, petechiae, attachment to diaphragm, liver and spleen, white to grey discoloured thick fluid containing blood clots, erosion, speckled fibrosis, hyperemia, bloody stomach fluids, slightly thickened stomach, enlarged stomach, or bedding and mucous substance in stomach. Histopathological evaluation showed gastritis and local erosion, necrosis of the apical mucosa. 4/5 males and 2/5 females had duodenum findings consisting of perforations from 0.5 - 1 cm in length, necrotic areas, greenish mucous fluid with blood clots, or blood clots. Histopathology of one female revealed ulcus, and purulent inflammation in the distal end. Further findings in males were speckled liver lobes (local chronic inflammation with necrosis), testicular atropy (diffuse interstitial and tubular necrosis), and focal peripheral coagulation necrosis of liver, small focal haemorrhages of kidney cortex. In females kidney findings were vacuolisation of proximal tubular cells, increased protein presence in distal tubules and Bowmans space, cortical petechiae, dilatation of distal tubules, diffuse hypertrophy, glomerular necrosis. One female had also enlarged adrenals and a mucous substance in the intestine.
Summarized results can be found in Attachment 1 in the attached background material.
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 1 800 mg/kg bw
- Quality of whole database:
- The available information comprises an adequate and reliable study, and is thus sufficient to fulfill the standard information requirements set out in Annex VII, 8.5, of Regulation (EC) No 1907/2006.
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 8 Apr - 3 Sep 1987
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 403 (Acute Inhalation Toxicity)
- Version / remarks:
- not specified
- Deviations:
- yes
- Remarks:
- methodological deficiencies (whole body exposure)
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 81-3 (Acute inhalation toxicity)
- Version / remarks:
- not specified
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Remarks:
- HSD:(SD) BR
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Sprague-Dawley, Inc. Houston, Texas, USA
- Age at study initiation: young adult
- Weight at study initiation: 242 - 350 g (male), 178 - 219 g (female)
- Housing: 1 - 3 per cage, males seperate from females, suspended wire bottom stainless steel cages
- Die: Purina Formulab Chow # 5008 ad libitum
- Water: tap water ad libitum
- Acclimation period: at least one week - Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- whole body
- Vehicle:
- other: dried filtered air
- Mass median aerodynamic diameter (MMAD):
- >= 3.9 - <= 4.5 µm
- Geometric standard deviation (GSD):
- >= 1.5 - <= 3
- Remark on MMAD/GSD:
- Please refer to "Any other information on materials and methods incl. tables"
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: stainless steel dynamic flow inhalation chamber
- Exposure chamber volume: 200 L
- Method of holding animals in test chamber: not reported
- System of generating particulates/aerosols: A stream of dry, filtered air was passed through either two (for thee lower exposure concentration) or four (for the higher exposure concentration) glass flasks containing the test material. The concentrated aerosol was then diluted with dried and filtered air and drawn into the exposure chamber.
- Method of particle size determination: Andersen cascade impactor
- Treatment of exhaust air: not reported
- Temperature, humidity, pressure in air chamber: Temperature: 8.9 - 20 °C, Humidity: 67 - 71%
TEST ATMOSPHERE
- Brief description of analytical method and equipment used: particle size was determined gravimetrically twice per h
- Samples taken from breathing zone: yes - Analytical verification of test atmosphere concentrations:
- yes
- Remarks:
- The concentration of the test atmosphere was determined gravimetrically twice per h, the particle size determination was performed using an Andersen cascade impactor.
- Duration of exposure:
- 4 h
- Concentrations:
- Nominal concentrations: 6.90, 14.1, 32.03 mg/L
Analytical concentrations: 2.06, 3.36, 5.04 mg/L (gravimetric) - No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations: Observations for mortality and pharmacological and/or toxicological effects were made frequently on the day of exposure and at least once daily thereafter for 14 days on all animals. Due to chamber design, only four animals (two males, and two females) could be observed during the exposure period.
- Necropsy of survivors performed: yes
- Body weight: Individual body weights were recorded prior to dosing and on day 7 and 14 or at the time of discovery of death. - Key result
- Sex:
- male
- Dose descriptor:
- LC50
- Effect level:
- > 5.04 mg/L air (analytical)
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Remarks on result:
- other: According to Litchfield and Wilcoxon
- Key result
- Sex:
- female
- Dose descriptor:
- LC50
- Effect level:
- 3.464 mg/L air (analytical)
- Based on:
- test mat.
- 95% CL:
- >= 2.98 - <= 4.03
- Exp. duration:
- 4 h
- Remarks on result:
- other: According to Litchfield and Wilcoxon
- Key result
- Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- 4.42 mg/L air (analytical)
- Based on:
- test mat.
- 95% CL:
- >= 3.09 - <= 6.32
- Exp. duration:
- 4 h
- Remarks on result:
- other: According to Litchfield and Wilcoxon
- Mortality:
- - 2.06 mg/L: 1/5 males (Day 1), 0/5 females
- 3.36 mg/L: 1/5 males (Day 2), 2/5 females (both Day 2)
- 5.04 mg/L: 1/5 males (Day 1), 5/5 females (Day 1, 2, 2 and 3) - Clinical signs:
- other: Please refer to "Any other informations incl. tables"
- Body weight:
- Reduced body weight was observed at Day 7 in all dose groups. However, body weight of the surviving animals recovered till the end of the observation period.
Summarized results can be found in Attachment 1 in the attached background material. - Gross pathology:
- The gross macroscopic examination of animals found dead between Day 1 and Day 3 after exposure revealed nasal discharge , salivation, lacrimation, polyuria, mottled red lungs and stomachs filled with gas and green-yellow paste. Except one male that showed mottled red lungs, no gross pathological abnormalities were noted in the animals sacrificed at the end of the post exposure observation period.
Summarized results can be found in Attachment 1 in the attached background material. - Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- The study was a guideline-conform study and conducted under GLP conditions.
Under the conditions of this study, the acute inhalation LC50 for 4-hour exposure was determined at 4.42 mg/L (371 mg/kg bw) for males and females combined, 5.04 mg/L (424 mg/kg bw) for males and 3.46 mg/L (290 mg/kg bw) for females.
In accordance with Regulation (EC) No 1272/2008 the test substance should be classified as acute toxic category 4 and the hazard statement H332 “harmful if inhaled” should be assigned.
Reference
Clinical signs of toxicity included decreased activity, constricted pupils, gasping, lacrimation, nasal discharge, piloerection, polyuria, ptosis and salivation during the exposure period and were further observed thereafter until Day 7 (2.06 mg/mL), Day 9 (3.36 mg/mL) and Day 10 (5.04 mg/mL) after treatment. No abnormalities were detected in surviving animals during the post exposure observation period from Day 11 onwards.
Summarized results can be found in Attachment 1 in the attached background material.
Summarized results (tabulated):
Dose [mg/L] |
Toxicological results* |
Duration of clinical signs |
Time of death |
Mortality (%) |
|
Males |
|||||
2.06 |
1/5/5 |
1/2h - day 7 |
day 1 |
20 |
|
3.36 |
1/5/5 |
1/2h - day 9 |
day 2 |
20 |
|
5.04 |
1/5/5 |
1/2h - day 10 |
day 1 |
20 |
|
LC50 < 5.04 mg/L |
|||||
Females |
|||||
2.06 |
0/5/5 |
1/2h - day 7 |
day 1 |
0 |
|
3.36 |
2/5/5 |
1/2h - day 8 |
day 2 |
40 |
|
5.04 |
5/5/5 |
1/2h - day 3 |
day 1, 2, 3 |
100 |
|
LC50 = 3.464 mg/L |
|||||
Combined |
|||||
2.06 |
1/10/10 |
-- |
-- |
10 |
|
3.36 |
3/10/10 |
-- |
-- |
30 |
|
5.04 |
6/10/10 |
-- |
-- |
60 |
|
combined LC50 = 4.42 mg/L |
* first number = number of dead animals, second number = number of animals with signs of toxicity, third number = number of animals used
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LC50
- Value:
- 3.46 mg/L air
- Physical form:
- inhalation: aerosol
- Quality of whole database:
- The available information comprises an adequate and reliable study, and is thus sufficient to fulfill the standard information requirements set out in Annex VIII, 8.5, of Regulation (EC) No 1907/2006.
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 14 - 28 May 1985
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Version / remarks:
- not specified
- Deviations:
- not specified
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 81-2 (Acute Dermal Toxicity)
- Deviations:
- yes
- Remarks:
- room temperature was twice increased for 12-14 hours above 20 2°C, due to a technical failure. This deviation was considered not to has affected the outcome of the study.
- GLP compliance:
- yes
- Test type:
- fixed dose procedure
- Limit test:
- yes
- Species:
- rabbit
- Strain:
- New Zealand White
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Broekman Institute, Someren, the Netherlands
- Age at study initiation: 18 weeks (male and female)
- Weight at study initiation: 2.7 - 2.9 kg (male), 2.8 - 3.0 kg (female)
- Housing: induvidually housed in metal cages
- Diet: standard laboratory animal diet
- Water: tap water ad libitum
- Acclimation period: 13 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 - 27
- Humidity (%): 60 - 85
- Photoperiod (hrs dark / hrs light): 12/12 - Type of coverage:
- semiocclusive
- Vehicle:
- water
- Details on dermal exposure:
- TEST SITE
- Area of exposure: mid-dorsal area
- % coverage: 10 (body surface)
- Type of wrap: surgical gauze fixed to aluminum foil
REMOVAL OF TEST SUBSTANCE
- Washing: with a wet paper tissue
- Time after start of exposure: 24 h - Duration of exposure:
- 24 h
- Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Observations for death or overt signs of toxicity were made during exposure and the following 14-day observation period. Body weights were noted prior to application of the test material on Day 0 and on Days 7 and 14.
- Necropsy of survivors performed: yes
- Erythema and Eschar Formation / Oedema Formation: After removal of the dressings and during the 14-day observation period. - Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Mortality:
- No mortality was observed.
- Clinical signs:
- other: No signs of systemic toxicity were noted throughout the study.
- Body weight:
- other body weight observations
- Remarks:
- Body weight development was not affected by the treatment.
- Gross pathology:
- No abnormalities were noted.
- Other findings:
- In the beginning of the study the treated skin surface generally showed slight erythema. Some areas revealed well-defined and moderate erythema. These signs were resolved one week after administration of the test susbtance.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Under the conditions of this study, the acute dermal LD50 of thiram was greater than 2000 mg/kg bw for both male and female rabbits.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- > 2 000 mg/kg bw
- Quality of whole database:
- The available information comprises an adequate and reliable study, and is thus sufficient to fulfill the standard information requirements set out in Annex VIII, 8.5, of Regulation (EC) No 1907/2006.
Additional information
To assess acute toxicity of the test substance, data after oral, inhalation and dermal exposure to the test substance are considered. All three studies were GLP-compliant, and performed in accordance with appropriate guidelines (EPA OPP 81-1, EPA OPP 81-3, EPA OPP 81-2)
Acute oral exposure to the test substance led to massive body weight loss, apathy, reduced locomotive activity, laboured breathing, ungroomed appearance, reduced faecal excretion, (half) closed and moist eyes, and tremors of the head. The acute oral LD50 of the test substance in the rat was 3700 mg/kg bw for male and 1800 mg/kg bw for female animals.
By dermal application the test substance showed only very low toxicity. No mortality was observed. The acute dermal LD50 of the test substance was > 2000 mg/kg bw in male and in female animals.
After whole body inhalation exposure to the test substance, observed toxicological effects consisted of activity decrease, constricted pupils, gasping, lacrimation, nasal discharge, piloerection, polyuria, ptosis, and salivation. The median lethal concentration (LC50) for the test substance in the rat was > 5.04 mg/L in male rats and 3.46 mg/L in female rats.
Justification for classification or non-classification
The available data on acute oral toxicity and acute inhalation toxicity meet the criteria for classification according to Regulation (EC) 1272/2008 and are therefore sufficient for classification of the test substance for acute oral toxicity category 4 (Acute Tox. 4, H302) and acute inhalation toxicity category 4 (Acute Tox. 4, H332). Based on the available data on acute dermal toxicity, no classification of the test substance for acute dermal toxicity is required.
The substance is listed in Annex VI of Regulation (EC) 1272/2008 (006-005-00-4). Harmonised classification in regard to minimum classification was adapted according to the available experimental data if appropriate.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.